OPEN ACCESS

ORIGINAL ARTICLE

High circulating angiopoietin-2 levels exacerbate pulmonary inflammation but not vascular leak or mortality in endotoxin-induced lung injury in mice

Kenny Schlosser,[1] Mohamad Taha,[1,2] Yupu Deng,[1] Lauralyn A McIntyre,[3] Shirley H J Mei,[1] Duncan J Stewart[1,2,4]

[1]Regenerative Medicine Program, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
[2]Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
[3]Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
[4]Department of Medicine, Division of Cardiology, University of Ottawa, Ottawa, Ontario, Canada

Correspondence to
Dr Duncan J Stewart, Regenerative Medicine, Ottawa Hospital Research Institute & University of Ottawa, Ottawa, Ontario K1H8L6, Canada; djstewart@ohri.ca

Check for updates

ABSTRACT

Background Elevated plasma levels of angiopoietin-2 (ANGPT2) have been reported in patients with acute lung injury (ALI); however, it remains unclear whether this increase contributes to, or just marks, the underlying vasculopathic inflammation and leak associated with ALI. Here we investigated the biological consequences of inducing high circulating levels of ANGPT2 in a mouse model of endotoxin-induced ALI.

Methods Transgenic mice (ANGPT2^{OVR}) with elevated circulating levels of ANGPT2, achieved through conditional hepatocyte-specific overexpression, were examined from 3 to 72 hours following lipopolysaccharide (LPS)-induced ALI. An aptamer-based inhibitor was used to neutralise the effects of circulating ANGPT2 in LPS-exposed ANGPT2^{OVR} mice.

Results Total cells, neutrophils and macrophages, as well as inflammatory cytokines, were significantly higher in bronchoalveolar lavage (BAL) of ANGPT2^{OVR} versus littermate control^{tTA} mice at 48 hours and 6 hours post-LPS, respectively. In contrast, LPS-induced vascular leak, evidenced by total BAL protein levels and lung wet/dry ratio, was unchanged between ANGPT2^{OVR} and controls^{tTA}, while BAL levels of IgM and albumin were decreased in ANGPT2^{OVR} mice between 24 hours and 48 hours suggesting a partial attenuation of vascular leak. There was no significant difference in LPS-induced mortality between ANGPT2^{OVR} and controls^{tTA}. An ANGPT2-neutralising aptamer partially attenuated alveolar cell infiltration while exacerbating vascular leak in LPS-exposed ANGPT2^{OVR} mice, supported by underlying time-dependent changes in the lung transcriptional profiles of multiple genes linked to neutrophil recruitment/adhesion and endothelial integrity.

Conclusions Our findings suggest that high circulating ANGPT2 potentiates endotoxin-induced lung inflammation but may also exert other pleiotropic effects to help fine-tune the vascular response to lung injury.

INTRODUCTION

Acute respiratory distress syndrome (ARDS) is a life-threatening condition for which there is currently no specific pharmacological treatment.[1] Pulmonary inflammation and vascular leak are hallmarks of acute lung injury (ALI) seen in ARDS, which may be mediated in part through dysregulation of the angiopoietin–Tie2 signalling axis.[2] Angiopoietin-1 (ANGPT1) and angiopoietin-2

Key messages

What is the key question?
► Elevated plasma levels of angiopoietin-2 (ANGPT2) in acute lung injury (ALI)/acute respiratory distress syndrome patients are associated with poor prognosis; however, it remains unclear whether these elevated circulating levels are just a marker or mediator of underlying pulmonary vascular dysfunction.

What is the bottom line?
► For the first time, this study demonstrates that elevated plasma levels of ANGPT2 play a context-dependent role in fine-tuning the inflammatory response to ALI.

Why read on?
► The isolated elevation of circulating ANGPT2 via hepatocyte-specific overexpression and secretion exacerbated pulmonary inflammation, but not vascular leak, and did not alter mortality in a murine model of bacterial endotoxin-induced ALI.

(ANGPT2) are ligands for the endothelial cell (EC)-enriched TIE2 receptor tyrosine kinase. Paracrine release of ANGPT1 from pericytes promotes TIE2 receptor phosphorylation and downstream activation of signalling pathways that protect against inflammation[3 4] and vascular leak.[5–7] In contrast, ANGPT2 (stored in Weibel-Palade bodies of ECs) has been shown to competitively inhibit ANGPT1-induced TIE2 phosphorylation in vitro, and its transgenic overexpression in the mouse embryo has been reported to cause defects in vascular development mimicking those seen in *ANGPT1* and *TIE2* knockout animals.[8–10] While these early observations support the classic view of ANGPT2 as a natural TIE2 antagonist and vascular destabilising factor,[9] there is increasing evidence that ANGPT2 may also function as a TIE2 agonist and vasculoprotective factor in a context-dependent manner. A number of in vitro studies have shown that ANGPT2 can activate the TIE2 receptor under various circumstances including in non-ECs lacking inhibitory coreceptors,[11] over extended periods of time[12] or at very high concentrations.[13 14] In vivo studies in mice have also shown that ANGPT2

can inhibit vascular leak induced by inflammatory stimuli such as mustard oil.[15] Thus, the role of ANGPT2 may vary widely from vasculopathic to vasculoprotective factor depending on the specific biological context.

In clinical settings, plasma levels of ANGPT2 have been shown to be elevated in patients with inflammatory disorders, in particular ALI/ARDS and sepsis,[16–20] and in some cases were associated with the severity of lung injury[21] and mortality.[17] However, while these observational studies establish the clinical relevance of ANGPT2 and suggest a potential role as a prognostic biomarker, they provide limited information on whether the elevated circulating levels contribute causally to underlying disease activity in ALI. To date, and to the best of our knowledge, no study has directly interrogated the potential contributory role of high circulating levels of ANGPT2 in an animal model of ALI.

Here, we hypothesised that endotoxin-induced ALI would be exacerbated by systemic ANGPT2 overexpression. High plasma levels of ANGPT2 were induced in transgenic mice (ANGPT2^{OVR}) independent of lung injury, via conditional hepatocyte-driven overexpression and secretion, and the effects on pulmonary vascular inflammation, permeability and mortality were then evaluated in the lipopolysaccharide (LPS)-induced model of ALI. Neutralisation of the circulating ANGPT2 in ANGPT2^{OVR} mice, via aptamer-based inhibition, was used to further probe the potential causal role of ANGPT2 on pulmonary inflammation and leak and identify molecular pathways involved in ANGPT2-mediated pulmonary transcriptional reprogramming.

MATERIALS AND METHODS

Peripheral blood samples from healthy subjects were obtained with informed written consent between years 2011 and 2014 at a single centre, in accordance with protocols and regulations approved by the Ottawa Hospital Research Ethics Board (#2011470–01H). Peripheral blood samples from patients with ALI/ARDS secondary to septic shock were obtained with informed written consent in 2009 in accordance with protocols and regulations approved by the respective research ethics boards in the multicentre PRECISE pilot trial.[22] All animal procedures were approved by the University of Ottawa's Animal Care Ethics Committee and complied with the principles and guidelines of the Canadian Council on Animal Care. All animal, cellular and molecular experiments and related data analysis were conducted over a period of 7 years from 2010 to 2017.

Transgenic overexpression of ANGPT2

High systemic circulating levels of human ANGPT2 (hANGPT2) were achieved with a doxycycline (Dox)-based conditional transgenic mouse system as described previously.[23] Of note, transgenic overexpression of ANGPT2 in mouse embryos has previously been shown to lead to midgestational embryonic lethality.[9] In the conditional system used in the current study, the tetracycline transactivator (tTA; driver transgene) expressed from a liver-specific promoter binds to tetracycline operator sequences upstream of the *ANGPT2* responder transgene. In the presence of the tetracycline analogue, Dox (Harlan chow), the expression of ANGPT2 is blocked. In this conditional system, the expression of ANGPT2 was induced by the dietary withdrawal of Dox. All mice were taken off Dox at 3 weeks and used for experiments at 8–10 weeks of age. Double transgenic ANGPT2^{OVR} mice (containing both the tTA driver gene and *ANGPT2* responder gene) and single transgenic littermate control^{tTA} mice (containing just the tTA driver gene) were

confirmed by PCR genotyping using DNA extracted from ear biopsies and transgene-specific primers as described previously.[23] Mice were on a CD1 genetic strain background. ANGPT2^{OVR} mice were indistinguishable in size and appearance from littermate controls and represented approximately 25% of each litter.

LPS-induced model of ALI

Mice received an intratracheal instillation of LPS (*Escherichia coli* 055:B5; 1 mg/kg or 500 000 EU/kg body weight in normal saline; Sigma), and blood, bronchoalveolar lavage (BAL) and lungs were collected after 3 hours, 6 hours, 24 hours, 48 hours and 72 hours. Of note, data for each time point represent a separate set of mice rather than serial measurements from a single set of mice. An LPS dose of 10 mg/kg was used in experiments to assess LPS-induced mortality.

Anti-ANGPT2 aptamer treatment in ANGPT2^{OVR} mice

The anti-ANGPT2 RNA aptamer, which binds to hANGPT2 protein, was developed previously.[24] The aptamer and a scrambled sequence control RNA were synthesised by Samchully Pharmaceutical (Seoul, Korea), with 2′-fluoropyrimidines and terminal 3′−3′ inverted deoxythymidine caps for nuclease resistance. The non-functional control RNA was composed of the same number and type of chemically modified nucleotides, but the sequence of nucleotides was randomly scrambled. Aptamer or scrambled-sequence control RNA (0.1 mg/kg, dissolved in phosphate buffered saline (PBS)) were injected in ANGPT2^{OVR} mice via tail vein injection by an operator that was blinded to the treatment status. No transfection agent was used with the aptamer or scrambled control RNA to minimise the potential for cellular uptake. All mice were then given LPS (1 mg/kg) via intratracheal instillation (within 5 min). Mice were euthanised for BAL analysis after 48 hours.

Biochemical measurements

Total protein levels in BAL were measured by bicinchoninic acid (BCA) assay. IgM and albumin levels in BAL were measured by ELISA (IgM, cat# E90-101; albumin, cat# E90-134, Bethyl laboratories) according to manufacturer instructions. ANGPT and TIE2 protein levels were measured by ELISA (hANGPT2, cat# DANG20, R&D Systems; mouse ANGPT2, cat# MANG20, R&D Systems; mouse ANGPT1, cat# EK1296, Boster Biological Tech Co. Ltd.; mouse total TIE2, cat #DYC762, R&D Systems; mouse phospho-TIE2 (p-TIE2), cat# DYC2816, R&D Systems) according to manufacturer instructions. BAL cytokine levels (cat# MAGPMAG-24K, Millipore) and phospho Akt/total Akt levels (cat# 48-618MAG, Millipore) in mouse lung homogenates were measured by multiplex magnetic bead-based luminex kits and run on a Bioplex 200 system (Biorad).

Statistics

The unpaired two-sided Student's t-test (for parametric data) or Mann-Whitney U test (for non-parametric data) were used for two-group comparisons as appropriate. Gaussian distributions were assessed using the D'Agostino Pearson omnibus normality test. For three or more group comparisons, one-way or two-way analysis of variance was performed with post hoc tests for individual p values with or without adjustment for multiple comparisons as reported in each figure legend. Gene expression profiling was corrected for multiple comparisons using the false discovery rate (FDR) method. In order to minimise false-negative interpretation of time course experiments (without increasing sample sizes post hoc), individual p values were reported with no

Figure 1 Circulating levels of human ANGPT2 are elevated in patients with ALI/ARDS and in ANGPT2[OVR] transgenic mice. (A) Characteristics of healthy subjects and patients with indirect ALI/ARDS (secondary to septic shock). (B) Plasma levels of ANGPT2 assessed in healthy subjects (n=12) and patients with indirect ALI/ARDS (n=8) at several time points following admission to the ICU (n=4–7/time point, subject to sample availability). Plasma specimens were not available for all time points. Kruskal-Wallis and Dunn's multiple comparison adjusted *p<0.05, **p<0.01, ***p<0.001 versus healthy control group. (C) Plasma levels of hANGPT2 expressed in transgenic mice with and without LPS exposure (n=5–8 mice/group/time point). hANGPT2 was ND in control (tTA) mice lacking the *hANGPT2* responder gene. Two-way analysis of variance and Bonferroni multiple comparison adjusted ***p=0.0001, ****p<0.0001 versus ctrl[tTA] group. Box plots denote median, IQR and min/max. ALI, acute lung injury; ANGPT2, angiopoietin-2; ARDS, acute respiratory distress syndrome; FiO2, fractional inspired oxygen; hANGPT2, human ANGPT2; ICU; intensive care unit; LPS, lipopolysaccharide; ND, not detectable; PaO_2, partial pressure arterial oxygen.

formal correction for multiple comparisons as recommended elsewhere.[25] Predefined samples sizes of approximately 8–12 mice/group were targeted, representing a pragmatic balance between statistical power (based on estimations of variation and effect size observed in pilot experiments), and animal breeding constraints. Statistical tests were performed with GraphPad Prism V.7.0 and Partek Genomics Suite. Specific statistical tests are presented in figure legends. All tests were performed two sided, and a significance level of p≤0.05 was considered statistically significant.

An expanded version of the materials and methods is provided as an online supplementary data.

RESULTS
Plasma levels of ANGPT2 are significantly elevated in patients with ALI/ARDS and in ANGPT2[OVR] transgenic mice

We first sought to characterise the plasma levels of ANGPT2 in a cohort of healthy subjects and patients with ALI/ARDS (secondary to septic shock) to define the level and variability associated with relevant clinical plasma specimens (figure 1A). At time of admission to the intensive care unit, patients with ALI/ ARDS showed significantly higher plasma levels of ANGPT2 compared with healthy subjects (median (IQR), ALI/ARDS: 17.5 (7.5–35.1) ng/mL vs healthy: 2.4 (1.6–3.1) ng/ mL) (figure 1B), which remained elevated at 6 hours, 12 hours, 24 hours, 72 hours and 7 days post admission. Plasma levels of ANGPT2 were quite variable between patients with ALI/ARDS, ranging from 4 to 130 ng/mL. These plasma levels of ANGPT2 are consistent with several previous independent studies of patients with direct or indirect ALI/ARDS,[17 26–28] which have reported median levels ranging from 15 to 20 ng/mL and maximal levels up to 115 ng/mL (online supplementary Figure S1). By comparison, transgenic ANGPT2[OVR] mice exhibited median hANGPT2 plasma levels of 213 ng/mL assessed at baseline and confirmed up to 72 hours after exposure to the bacterial endotoxin, LPS, demonstrating very robust expression and secretion into the systemic circulation (figure 1C). Littermate controls[tTA] lacking the *hANGPT2* responder gene showed no detectable levels of hANGPT2 in plasma (figure 1C). Plasma levels of mouse ANGPT2 were relatively stable following LPS exposure, with only a modest

(~2-fold) and transient decline at 3 hours and 6 hours post-LPS (online supplementary figure S2). Thus, systemic hANGPT2 overexpression provides elevated circulating levels of ANGPT2 independent of LPS-induced lung injury. In addition, plasma levels of murine ANGPT2 were slightly higher in ANGPT2^{OVR} versus control^{tTA} mice, though the difference only reached statistical significance at 3 hours and 24 hours post-LPS (online supplementary figure S2).

LPS-induced pulmonary inflammation is exacerbated in ANGPT2^{OVR} mice

ALI was induced via endotracheal delivery of LPS, and an initial dose–response experiment was conducted in control^{tTA} mice to define an LPS dose that would induce inflammation but not saturate the biological readout of total cell infiltration of the alveolar air space. This was an important consideration to reduce the likelihood of potential false-negative outcomes associated with a saturated biologic response to LPS, since we hypothesised that systemic ANGPT2 overexpression would increase pulmonary inflammation. A 1 mg/kg LPS dose induced a significant increase (~6-fold, $p < 0.05$) in total cell levels in BAL 48 hours postdelivery (compared with sham mice) but did not saturate the response as demonstrated by a linear increase in cell infiltration at higher doses (figure 2A). In subsequent time course experiments, total and differential cell counts in BAL were assessed over a range of early and late time points including 3 hour, 6 hour, 24 hours, 48 hours and 72 hours post-LPS exposure. Total cell, neutrophil and macrophage/monocyte cell counts were significantly elevated in the BAL of ANGPT2^{OVR} mice versus controls^{tTA} at 48 hours post-LPS exposure ($p < 0.05$, figure 2B), consistent with a pro-inflammatory role for ANGPT2. Four proinflammatory cytokines were also measured in the BAL fluid at both an early (6 hours) and late (48 hours) time point following LPS-induced injury (figure 2C). The levels of interleukin (IL)-6, IL-1β and monocyte chemoattractant protein-1 (MCP-1) were significantly higher ($p < 0.05$) in ANGPT2^{OVR} mice versus controls^{tTA} specifically at the 6 hours endpoint, again supporting a proinflammatory role for the elevated circulating levels of ANGPT2 in this model. No significant difference in tumour necrosis factor-alpha (TNF-α) levels were observed at 6 hours or 48 hours.

LPS-induced pulmonary vascular leak is not exacerbated in ANGPT2^{OVR} mice

Pulmonary vascular leak was initially assessed by measuring the total protein level in BAL fluid, which is expected to rise with increasing vascular permeability. However, while total protein levels in BAL progressively increased in a time-dependent response to LPS exposure, no significant increase was observed in ANGPT2^{OVR} mice compared with controls^{tTA} (figure 3A). Importantly, the possibility of a false-negative result caused by saturation of the biological response to LPS is unlikely, because the LPS dose was confirmed to induce only submaximal vascular leak in LPS-titration experiments and was near the lower end of the linear dynamic range of BAL total protein measurements (figure 3B). Pulmonary oedema, as evidenced by the lung wet/dry weight ratio, was significantly increased at 24 hours and 48 hours post-LPS exposure ($p < 0.05$ vs mice that did not receive LPS); however, there were no significant differences between the ANGPT2^{OVR} mice and controls^{tTA} at either time points (figure 3C). BAL levels of the two plasma proteins IgM and albumin, which represent more specific and sensitive markers of vascular permeability, were also measured to further assess pulmonary leak (figure 3D). Interestingly, while BAL levels of IgM and albumin increased time-dependently in response to LPS exposure, consistent with increased vascular permeability in the LPS model, the levels of these specific proteins showed marked attenuation in ANGPT2^{OVR} mice compared with controls^{tTA} at the 24 hours and 48 hours endpoints ($p < 0.05$). These results suggest that high plasma levels of ANGPT2 might provide partial protection against LPS-induced vascular leak, which would support a previous report in which ANGPT2 was also shown to decrease vascular leak in mice exposed to another type of inflammatory agent.[15]

Systemic overexpression of ANGPT2 neither promotes nor protects against LPS-induced mortality

In light of the contrasting effects on lung vascular inflammation and leak, we sought to determine whether the net effect of high circulating ANGPT2 levels would be detrimental or beneficial to the survival of mice with severe LPS-induced lung injury (figure 4). However, no significant difference in survival was observed in this model: 39% of control^{tTA} mice (14 of 37 mice) and 37% (14 of 38 mice) of ANGPT2^{OVR} mice exhibited terminal morbidity by day 5, with no further events observed up to the predefined experimental endpoint on day 10.

Pulmonary changes in angiopoietin expression and TIE2 receptor activation

The pulmonary regulation of endogenous mouse *Angpt1*, *Angpt2* and *Tie2* expression was examined to gain further insight into the potential context-dependent actions of *Angpt2*.[13 14] At baseline (ie, prior to LPS exposure), mouse *Angpt1* mRNA levels were ~4-fold higher than *Angpt2* (figure 5A vs figure 5C); however, *Angpt1* expression progressively decreased (up to ~16-fold by 48 hours post-LPS exposure; figure 5A), while the expression of *Angpt2* remained relatively fixed near baseline levels, with only a transient decrease (~2–4 fold, $p < 0.05$) at earlier time points (figure 5C). A similar pattern in angiopoietin expression was also observed at the protein level, though the rate and magnitude of change were more modest (figure 5B,D). Lung mRNA levels of *Tie2* showed a progressive and significant decline after LPS exposure ($p < 0.0001$, figure 5E), which was also detectable at the protein level, although to a lesser extent and with delayed kinetics (figure 5F). Of note, no significant differences were detected between control^{tTA} and ANGPT2^{OVR} mice in ANGPT1, ANGPT2 and TIE2 levels at the mRNA or protein levels at baseline and after LPS exposure (figure 5). Pulmonary transcript levels of *Vegfa* were also compared between ctrl^{tTA} and ANGPT2^{OVR} mice (online supplementary figure S3), given its importance in vascular permeability[29 30] and potential for crosstalk with TIE2 signalling pathways[31]; however, no significant differences were observed between transgenic mouse groups at baseline or after LPS exposure. We next sought to investigate pulmonary TIE2 receptor activation using the ratio of pTIE2 to total TIE2 as a readout (figure 5G). An initial decline in pTIE2/TIE2 was observed from baseline to 6 hours post-LPS exposure (−2.3 mean fold change for ANGPT2^{OVR} and −3.9 fold change for ctrl^{tTA}, $p < 0.0001$ vs baseline), followed by a recovery to baseline levels by 24 hours in both ctrl^{tTA} and ANGPT2^{OVR} mice. Importantly, however, in ANGPT2^{OVR} but not control^{tTA} mice, TIE2 phosphorylation was enhanced 1.7-fold above baseline levels at 24 hours ($p < 0.05$), consistent with a potential time-dependent agonist role for circulating ANGPT2.

Figure 2 Inflammatory cell infiltration and cytokine levels are elevated in the alveolar air space of LPS-exposed ANGPT2[OVR] mice. (A) Bronchoalveolar lavage (BAL) total cell counts at different LPS doses in control[tTA] mice 48 hours after intratracheal LPS delivery (n=3–5 mice/LPS dose). Data represent mean±SEM. Red lines denote linear trend line and error (dotted lines). (B) BAL cell counts at different time points following LPS-induced lung injury. White squares denote control[tTA] mice, and grey circles denote ANGPT2[OVR] mice. Time 0 hour (no LPS): n=7 mice/group, 3 hours: n=7–8 mice/group, 6 hours: n=9–10 mice/group, 24 hours: n=9–10 mice/group, 48 hours: n=11–14 mice/group and 72 hours: n=9–10 mice/ group). Data represent two independent animal experiments per time point. Red horizontal line and error bars denote mean±SEM. Two-way analysis of variance and Fisher's LSD test. p values are shown unadjusted for multiple comparisons. (C) Proinflammatory cytokine levels in BAL fluid at two different time points following LPS exposure. Time 6 hours: n=9–12/group, 48 hours: n=11/group. Data represent two independent animal experiments per time point. White squares denote control[tTA] mice, and grey circles denote ANGPT2[OVR] mice. Red horizontal line and error bars denote mean±SEM. Unadjusted p values are shown. ANGPT2, angiopoietin-2; IL, interleukin; LPS, lipopolysaccharide; MCP-1, monocyte chemoattractant protein-1; TNF-α, tumour necrosis factor-alpha.

Figure 3 LPS-induced pulmonary vascular leak is not exacerbated in ANGPT2[OVR] mice. (A) Bronchoalveolar lavage (BAL) levels of total protein at different time points following LPS-induced lung injury. (B) Pilot experiment demonstrating subsaturating total protein levels in BAL of control[tTA] mice 48 hours after LPS exposure (n=3–5 mice/LPS dose). Error bars denote SEM. Red line shows linear trend line and associated error (dotted lines). (C) Assessment of pulmonary oedema by the lung wet/dry weight ratio. One-way analysis of variance (ANOVA) and Dunnet's multiple comparison test. *$p<0.05$, **$p<0.01$, ****$p<0.0001$ versus no LPS group. (D) BAL levels of IgM and albumin at different time points following LPS exposure. White squares denote control[tTA] mice, and grey circles denote ANGPT2[OVR] mice. Two-way ANOVA and Fisher's LSD test (p values unadjusted for multiple comparisons). For panels (A), (C) and (D), red horizontal lines and error bars denote mean±SEM. Sample sizes in time course experiments were time 0 hour (no LPS): n=7 mice/group, 3 hours: n=7–8 mice/group, 6 hours: n=9–10 mice/group, 24 hours: n=9–10 mice/group, 48 hours: n=11–14 mice/group, 72 hours: n=9–10 mice/group). Data represent two independent animal experiments per time point. ANGPT2, angiopoietin-2; LPS, lipopolysaccharide.

Lung transcriptional profiling reveals dynamic temporal regulation of diverse vascular genes in response to LPS-induced injury

To gain insight into underlying molecular mechanisms, we measured the pulmonary mRNA expression of 84 genes known to be involved in critical signalling pathways related to vascular biology including angiogenesis, vascular tone, inflammation, apoptosis, cell adhesion, coagulation and platelet activation. Because the actions of ANGPT2 are known to be highly context dependent, we first sought to establish a framework to understand the temporal regulation of these genes in response to LPS, independent of high circulating ANGPT2 levels. Therefore, transcript levels were first investigated in control[tTA] mice at baseline (no LPS) and two representative time points after LPS exposure to assess both an early (6 hours) and later (48 hours) phase of lung injury. All but one gene showed a significant change in expression following LPS exposure (FDR <0.05, ranging from 43-fold down to 190-fold up

versus baseline (no LPS) group; figure 6A and Table E1 in the online supplementary data), and their temporal regulation was evident by the distinct expression patterns observed at 6 hours and 48 hours, as reflected in the hierarchical clustering of mice (figure 6A). Proinflammatory cytokines/chemokines such as *IL-1b*, *Ccl2*, *TNF-α*, *Cxcl1* and *Cxcl2* were the most highly upregulated genes (from 23-fold to 190-fold elevated), and several key genes linked to vascular integrity, such as *Cdh5*, *Ocln* and *Angpt1*, were all significantly downregulated (from −7 fold to −44 fold decreased), consistent with the lung inflammation and vascular leak observed in this LPS model. The lung transcript profiles also revealed differences in how gene expression within different functional groups of related genes were regulated time-dependently between the early and late phases of lung injury. The inflammation group showed the highest proportion of genes with peak changes in expression at 6 hours, and the most balanced distribution, with 46% and 54% of genes showing maximal changes at 6 hours and

Figure 4 Survival following high-dose LPS challenge. Intratracheal administration of 10 mg/kg LPS in ANGPT2^{OVR} and control^{tTA} (Ctrl) littermate mice. Survival curves were not significantly different by log-rank test (n=37–38 mice/group, from five independent animal experiments). ANGPT2, angiopoietin-2; LPS, lipopolysaccharide.

48 hours, respectively (figure 6B). By comparison, peak changes in the expression of cell adhesion-linked genes (that may also play important roles in barrier function) was skewed markedly towards the later phase of lung injury, with 35% and 65% of these genes peaking at 6 hours and 48 hours, respectively. Genes associated with apoptosis, platelet activation and vascular tone were the most disproportionately regulated, with 79%–88% showing peak changes in expression at 48 hours.

Proinflammatory and barrier-stabilising genes are time-dependently upregulated in ANGPT2^{OVR} mice after LPS injury
We next sought to evaluate the effects of elevated plasma ANGPT2 levels on pulmonary gene expression before and after LPS exposure. Under baseline physiological conditions (ie, no LPS exposure), there were no significant differences in the lung transcript profile between ANGPT2^{OVR} and control^{tTA} mice (table E2 in the online supplementary data), suggesting that even high plasma levels of ANGPT2 may not alter lung vascular biology under normal physiological conditions. Similarly, at 6 hours post-LPS exposure, no significant differences in lung gene expression were detectable between ANGPT2^{OVR} and control^{tTA} mice (table E3 in the online supplementary data). However, at 48 hours post-LPS exposure, ANGPT2^{OVR} mice exhibited significant alterations in the expression of 59 genes (FDR <0.05 vs control^{tTA} mice; figure 7A,B and table E4 in the online supplementary data), including representatives from each of the functional groups described previously. The magnitude of change in transcript levels triggered by systemic ANGPT2 over-expression was modest (ie, mean change; −1.6-fold down and 2.4-fold up) compared with the changes induced by LPS exposure (ie, mean change; −7.4 fold down and 16.6-fold up at 48 hours), which is consistent with the moderate effects ANGPT2^{OVR} mice showed on neutrophil infiltration (figure 2) and vascular leak in the lungs (figure 3). Interestingly, the proinflammatory mediators that were increased by LPS exposure in control^{tTA} mice

(ie, *lL-1b*, *Ccl2*, *Tnfα*, *Cxcl1* and *Cxcl2)* were not increased further in the ANGPT2^{OVR} mice at 48 hours; however, a separate set of genes known to promote neutrophil adhesion and recruitment such as *IL-7*,[32] endothelin-1 (*Edn1*),[33] plasminogen activator tissue (*Plat*),[34] ACE[35] and chemokine (C-X3-C motif) ligand 1 (also known as fractalkine, *Cx3cl1*) were significantly elevated (figure 7C). This suggests that multiple molecular mechanisms may act to potentiate pulmonary inflammation. ANGPT2^{OVR} mice also showed increased expression of several genes that were decreased by LPS exposure and that are known to promote endothelial barrier integrity, such as occludin (*Ocln*), thrombomodulin (*Thbd*) and integrins (*Itgb1*, *Itgb3* and *Itgav*) (figure 7C).

In vivo neutralisation of circulating ANGPT2 partially reverses the effects on lung vascular inflammation and leak in LPS-injured mice
To confirm whether the high circulating levels of ANGPT2 directly contributed to the observed effects on lung vascular inflammation and leak, an aptamer-based inhibitor[24] was used to neutralise the extracellular circulating ANGPT2 in ANGPT2^{OVR} mice exposed to LPS. This aptamer has previously been shown to bind to hANGPT2 protein with high affinity and specificity.[24] The ability of the aptamer to selectively block ANGPT2-mediated TIE2 activation, but not ANGPT1-mediated TIE2 activation, was first confirmed in vitro using a TIE2 receptor phosphorylation assay (figure 8A). In a cultured EC system, ANGPT2 does not induce robust phosphorylation of TIE2 except at very high concentrations[24]; therefore, a more practical assay system was adopted to validate the inhibitory action of the aptamer using HEK-293 cells that ectopically express TIE2, as described previously.[24] The anti^{ANGPT2} aptamer effectively blocked TIE2 phosphorylation induced by recombinant human (rh) ANGPT2 (p<0.0001) but did not block TIE2 phosphorylation induced by rhANGPT1 (figure 8A, lanes 1–6). This effect was specific to the aptamer, as no inhibition of TIE2 phosphorylation was observed with a scrambled-sequence control oligonucleotide. To further delineate the potential mechanism by which the aptamer blocks TIE2 phosphorylation, we also examined its neutralising effects in the presence of both rhANGPT2 and rhANGPT1 simultaneously (figure 8A, lanes 7–9). This is important because the aptamer could prevent ANGPT2 from binding to the TIE2 receptor, or simply prevent dimerisation of the receptor (which is necessary for TIE2 phosphorylation) after ANGPT2 binds to TIE2; however, the former mechanism would be more effective since it would not interfere with interactions between ANGPT1 and TIE2. In the presence of both rhANGPT2 and rhANGPT1, the level of TIE2 phosphorylation was significantly attenuated in cells treated with the aptamer (p<0.001 vs no aptamer, figure 8A, lane 8 vs 7), but still significantly higher (p<0.05) than cells treated with only rhANGPT2 and aptamer (figure 8A, lane 3), and on par with cells treated only with ANGPT1 and aptamer (figure 8A, lane 6). Collectively, these results support a mechanism in which the aptamer selectively blocks ANGPT2-mediated TIE2 activation and does not interfere with the interaction between ANGPT1 and TIE2.

The in vivo effects of neutralising circulating ANGPT2 in ANGPT2^{OVR} mice was then evaluated by intravenous administration of the aptamer or scrambled-sequence control just prior to LPS exposure. A non-significant but consistent trend towards decreased BAL levels of total cells (1.7-fold decrease, p=0.07), neutrophils (1.4-fold decrease, p=0.13) and macrophage/monocytes (1.5-fold decrease, p=0.06) was observed

Figure 5 Changes in pulmonary levels of ANGPT1, ANGPT2, TIE2 and pTIE2/TIE2. (A, C andE) Lung mRNA levels of mouse *Angpt1*, *Angpt2* and *Tie2* in control[tTA] mice (open squares) and ANGPT2[OVR] mice (grey circles). Left panel shows mRNA levels measured by RT-qPCR at baseline (ie, time 0, no LPS) presented in relative expression units (normalised to the geomean of *Gapdh* and *β-actin*). Right panel shows the change in mRNA levels after LPS exposure. Data are presented as fold change to baseline and log2 transformed; n=7–11 mice/genotype group/time point). (B, D and F) Lung protein levels of mouse ANGPT1, ANGPT2 and TIE2 measured by ELISA. Left panel shows protein levels at baseline normalised to total protein levels. Right panel shows the change in protein levels after LPS exposure. Data are presented as fold change to baseline and log2 transformed; n=7–9 mice/genotype group/time point. (G) Ratio of pTIE2 to total TIE2 protein at baseline (left panel) and after LPS exposure (right panel, presented as fold change to baseline and log2 transformed) n=7–9 mice/genotype group/time point. Error bars denote mean±SEM. For clarity, statistical tests for LPS-induced changes in mRNA and protein levels are only shown for the control[tTA] group (two-way analysis of variance (ANOVA) and Dunnett' s multiple comparison test; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 vs time 0), with the exception of panel F where significant differences were only detected in the ANGPT2[OVR] group. No significant differences between genotype groups were detected by two-way ANOVA and Sidak's multiple comparison test. ANGPT2, angiopoietin-2; LPS, lipopolysaccharide; pTIE2, phospho-TIE2.

Figure 6 Lung transcriptional profiling reveals dynamic temporal regulation of vascular genes in LPS-injured mice. (A) Hierarchical clustering of gene expression patterns in sham and LPS-exposed control[tTA] mice at 6 hours and 48 hours. The heatmap shows relative expression levels of 84 predefined genes that were assessed by PCR array. The right panel shows the mean fold change in expression of each gene at both 6 hours and 48 hours post-LPS versus the sham group. Data for 6 hours and 48 hours are superimposed on the graph to facilitate viewing. (B) The graph shows how gene expression across different functional groups is regulated between the early and later phases of lung injury, based on the percentage of genes that showed peak changes in expression (up or down) at 6 hours or 48 hours post-LPS exposure. LPS, lipopolysaccharide.

in the ANGPT2[OVR] mice treated with the anti[ANGPT2] aptamer (compared with ANGPT2[OVR] mice treated with the scrambled-sequence control; figure 8B). However, indices of vascular leak were concordantly increased in LPS-exposed ANGPT2[OVR] mice that received the anti[ANGPT2] aptamer as reflected in the increased BAL IgM (p=0.01) and albumin (p=0.06) levels

Figure 7 ANGPT2[OVR] mice show time-dependent alterations in pulmonary gene expression at 48 hours post-LPS exposure. (A) Number of genes significantly altered by systemic ANGPT2 overexpression before (time 0) and after LPS exposure. Eighty-four predefined genes linked to endothelial cell biology were measured by RT-qPCR in lung tissue. (B) Heatmap showing relative expression levels of 59 genes differentially expressed between control[tTA] (Ctrl) and ANGPT2[OVR] mice (FDR<0.05). (C) Bar graphs show relative mRNA levels of several genes that were significantly upregulated in ANGPT2[OVR] mice 48 hours post-LPS, with functional roles in neutrophil adhesion and recruitment (ie, proinflammatory) or endothelial barrier stabilisation. *p<0.05, **p<0.01 versus Ctrl[tTA]. Data are presented as mean±SEM (n=4/group). ANGPT2, angiopoietin-2; LPS, lipopolysaccharide.

(figure 8B), again consistent with a possible vasculoprotective role for circulating ANGPT2 in this model.

Targeted lung transcriptional profiling of 84 candidate genes was conducted once again to derive further mechanistic insight. A total of 16 genes were both significantly increased in LPS-exposed ANGPT2[OVR] mice (vs LPS-exposed control[tTA] mice) and subsequently attenuated by the anti[ANGPT2] aptamer treatment (FDR <0.05, figure 8C). Of note, aptamer-mediated neutralisation of circulating ANGPT2 in LPS-exposed ANGPT2[OVR] mice significantly blocked (FDR <0.05) the upregulation of genes linked to neutrophil adhesion and recruitment (ie, *IL-7*, *Edn1* and *Plat*), as well as endothelial barrier integrity (ie, *Ocln*, *Thbd*, *Itgav*, *Itgb1* and *Itgb3*). In addition, aptamer treatment

also attenuated the expression of several apoptosis-linked genes that could potentially exacerbate the inflammatory response through cell death mechanisms. To gain additional insight into the potential signalling pathways affected by the altered genes, we performed a gene set enrichment analysis using Partek Pathway. Among the top 10 pathways that were significantly enriched in genes altered by high plasma ANGPT2 levels after LPS injury (figure 8D), several were linked to vascular inflammation and permeability including cell adhesion molecules (rank 10), *Rap1* signalling (rank 8), ECM-receptor interaction (rank 6), focal adhesion (rank 3) and *PI3K-Akt* signalling (rank 1). The highest ranked pathway involved protein kinase B (AKT), which is known to be a central transducer of multiple cell signalling

Figure 8 In vitro and in vivo neutralisation of ANGPT2. (A) In vitro Tie2 phosphorylation assay demonstrates selective blockade of ANGPT2-mediated TIE2 receptor activation by an anti-hANGPT2 aptamer. HEK293 cells ectopically expressing human TIE2 were treated with various combinations of recombinant human ANGPT1 (rhANGPT1) (3 nM), rhANGPT2 (15 nM), the anti-ANGPT2 aptamer (Anti[ANGPT2]; 15 nM) or scrambled-sequence control RNA molecule (Scr[Ctrl], 15 nM). PhosphoTIE2 (pTIE2) was measured by immunoprecipitation (IP) for TIE2 followed by immunoblotting (IB) for phosphotyrosine (pTYR). Blots were stripped and reprobed for TIE2. Representative blots are shown. Summary data are presented as mean±SEM and expressed relative to baseline (lane 1) (n=3–5 independent experiments). One-way analysis of variance and Tukey's multiple comparison adjusted *p<0.05, ***p<0.001, ****p<0.0001. (B) In vivo effects of anti-ANGPT2 aptamer treatment in ANGPT2[OVR] mice following LPS-induced lung injury. ANGPT2[OVR] mice received a intravenous (IV) tail injection of aptamer (Anti[ANGPT2]) or scrambled control (Scr[Ctrl]) just prior to intratracheal (IT) LPS challenge. BAL levels of different cell and plasma proteins were measured 48 hours later. Data are presented as mean±SEM (n=12–13 mice/group, from three independent animal experiments). Exact p values are shown for unpaired two-sided t-tests. (C) Hierarchical clustering and heatmap showing relative expression and fold change levels of 16 genes that were significantly increased in ANGPT2[OVR] (Scr[Ctrl]) mice versus Ctrl[tTA] mice 48 hours post-LPS challenge and attenuated by Anti[ANGPT2] aptamer treatment (FDR <0.05). The mean fold change in expression of each gene is shown on the right for different group comparisons. (D) Top 10 pathways significantly enriched in genes altered by circulating ANGPT2 as determined by gene set enrichment analysis. (E) The ratio of phosphoAKT (Ser473) to total AKT protein in the lungs. Data are presented as mean±SEM (n=10–13 mice/group, from two independent experiments). Exact p value shown for Mann-Whitney U test. ANGPT2, angiopoietin-2; AKT, protein kinase B; ECM, extracellular matrix; FDR, false discovery rate; hANGPT2, human ANGPT2; LPS, lipopolysaccharide.

pathways. We therefore examined AKT protein phosphorylation (ie, pAKT/AKT ratio) in the lungs at 48 hours post-LPS. AKT phosphorylation was significantly increased (~5-fold above baseline) in control[tTA] mice 48 hours post-LPS injury (p<0.05, figure 8E), but this was significantly attenuated in ANGPT2[OVR] mice (figure 8E), suggesting that ANGPT2 may contribute to the resolution of lung injury through an AKT-dependent mechanism.

DISCUSSION

In this study, we investigated whether elevated plasma levels of ANGPT2 play a role in potentiating the lung vascular injury and mortality associated with ALI/ARDS in patients. Our results show that in transgenic mice with LPS-induced ALI, high plasma levels of ANGPT2 (induced independent of LPS-exposure by hepatocyte-specific overexpression and secretion) exert only modest effects on lung microvascular function, exacerbating inflammation but not vascular leak, with no effect on LPS-induced mortality.

Our finding that elevated plasma levels of ANGPT2 potentiated pulmonary inflammation during LPS-induced lung injury was supported by increases in proinflammatory cells and cytokines in the alveolar air space of mice. However, contrary to our original hypothesis, LPS-induced pulmonary vascular leak and oedema showed no change in ANGPT2[OVR] mice, based on BAL total protein levels and lung wet/dry weight ratios, respectively. Interestingly, more specific markers of vascular permeability such as IgM and albumin both appeared to be decreased in the BAL of ANGPT2[OVR] mice compared with controls[tTA], suggesting that elevated plasma levels of ANGPT2 might provide some partial protective effects under specific contexts in vivo. At the molecular level, these biological effects were supported by underlying changes in the pulmonary expression of multiple genes, including upregulation of genes known to be important for inflammatory mechanisms involving neutrophil adhesion and recruitment and upregulation of genes involved in endothelial barrier stability via cell–cell and cell–matrix junctional integrity. Interestingly, significant differences in the pulmonary gene expression profiles between ANGPT2[OVR] and control[tTA] mice were only evident under pathological (ie, post-LPS exposure) but not physiological conditions, suggesting that high plasma ANGPT2 levels are necessary but not sufficient alone to induce the observed effects on vascular inflammation and permeability, reinforcing the context-dependent pleiotropic actions of ANGPT2. The temporal regulation of these transcriptional changes, which occurred later in the time course of lung injury (at 48 hours post-LPS), coincided with a significant decline in the pulmonary levels of ANGPT1 and TIE2, suggesting a potential coordinated response to vascular injury. These changes have two potential interpretations with important implications. First, previous cell culture studies have shown that ANGPT2 can function as a dose-dependent antagonist of TIE2 when ANGPT1 is present, but as an agonist when ANGPT1 is absent,[14] suggesting that ANGPT2 activity could switch between antagonist and agonist as lung injury progresses over time. Thus, we speculate that stable or increased levels of ANGPT2 with context-induced agonist activity could serve as a potential negative feedback mechanism to compensate for decreased endothelial TIE2 signalling caused by the reduction in ANGPT1 and TIE2 levels. Second, the decrease in TIE2 levels could also favour indirect effects mediated through TIE2-independent or endothelial-independent mechanisms, which might contribute to the diverse transcriptional changes observed in the lung. These distinct mechanisms could include ANGPT2 signalling through

alternate endothelial receptors such as integrins,[36] or alternate TIE2-expressing cells such as neutrophils,[37] monocytes[38 39] and lung epithelials.[40]

The magnitude of effects induced by systemic ANGPT2 overexpression was relatively moderate compared with the effects of LPS exposure. Furthermore, broad transcriptional reprogramming was observed in the lungs of ANGPT2[OVR] mice compared with controls[tTA] after LPS exposure, which was associated with small changes in many different effector genes related to vessel function and homeostasis. Collectively, this suggests that circulating ANGPT2 may be better suited for fine-tuning the vascular response to lung injury, rather than driving major pathophysiological changes. This role would be consistent with the minimal impact that was observed on LPS-induced mortality in this model and the dynamic effects on pulmonary inflammation and leak. Gene set enrichment analysis identified the multifunctional protein kinase, *Akt*, which has an established role in blood vessel homeostasis,[41] as one of the key cellular transducers of these transcriptional changes. Previous studies have demonstrated that AKT activation may contribute to vascular leak in vivo[42] and the development of LPS-induced ALI.[43] In the current study, the elevation in lung AKT phosphorylation induced by LPS exposure was significantly attenuated in ANGPT2[OVR] mice compared with controls[tTA] at 48 hours, which suggests a potential homeostatic role for ANGPT2.

In the present study, ANGPT2[OVR] mice showed an enhanced inflammatory response to LPS exposure, which is consistent with the proinflammatory role of ANGPT2 that has been reported previously.[44] In contrast to some previous studies that have reported increased vascular leak when rhANGPT2 was injected in healthy mice,[45] our results suggest that ANGPT2 may attenuate vascular leak in mice with lung injury. The different physiological settings of these experiments is an important distinction given the increasing evidence that ANGPT2 activity may fluctuate based on the activation state of the endothelium.[46] In the context of LPS-induced lung injury, we observed a potential stress-dependent protective effect of ANGPT2. This result is consistent with findings by Yancoupolous' group, which have previously reported that ANGPT2 can function as an autocrine protective factor in ECs exposed to shear stress and can also inhibit vascular leak induced by inflammatory agents in mice.[15] The potential vascular protective effect of ANGPT2 is also supported by a report by Kurniati et al,[47] in which ANGPT2 deficient mice were shown to have higher albuminuria than wild-type controls in an intraperitoneal LPS model of acute kidney injury.[47] Moreover, these ANGPT2-deficient mice showed reduced endothelial adhesion molecule expression and neutrophil recruitment in the kidney, consistent with a proinflammatory effect of ANGPT2. Thus, the dissociation between inflammation and vascular integrity observed in our study is supported by several independent studies and under various contexts. In a study by Hegeman et al[48], administration of rhANGPT1 in mice with ventilator-induced lung injury decreased inflammation but not vascular leak. Changes in vascular permeability independent of inflammation have also been reported. David et al[49] showed that the synthetic TIE2 agonist, vasculotide, prevented endotoxaemia-induced pulmonary vascular leak in mice but failed to modulate markers of inflammation. In addition, the study by David et al demonstrated that vascular leak was attenuated through a mechanism involving TIE2 activation and signalling. Taken together, these studies suggest that inflammation and vascular leak can be modulated independently, and this dissociation likely involves more than one distinct mechanism. In our study, we speculate

that the differential effects of systemic ANGPT2 overexpression could potentially be reconciled through distinct cell type-specific activities. One possibility is that enhanced inflammation in LPS-injured ANGPT2^{OVR} mice could be due to the chemoattractant properties of ANGPT2, which has previously been shown to recruit TIE2-positive monocytes/macrophages and neutrophils,[37 38] while decreased vascular leak could be mediated separately through the ANGPT2-dependent activation of endothelial TIE2. Consistent with this idea, Han and colleagues have recently shown that administration of the ANG2-binding and TIE2-activating antibody (ABTAA), which triggers ANGPT2 clustering and subsequent activation of the TIE2 receptor, effectively attenuated LPS-induced pulmonary vascular leak in a sepsis mouse model.[50] This is also consistent with the dynamic changes in TIE2 phosphorylation detected in pulmonary tissue in our model, which showed an initial decline in TIE2 activation (ie, pTIE2/TIE2 ratio) from 3 hours to 6 hours post-LPS, followed by a recovery at 24 hours post-LPS that exceeded baseline levels specifically in ANGPT2^{OVR} but not control^{tTA} mice.

One limitation of our study is that ANGPT2 expression was induced several weeks prior to LPS exposure to facilitate robust elevation in circulating levels. Therefore, this model may not recapitulate the acute release of ANGPT2 from endothelial Weibel-Palade bodies that is presumed to occur in the context of clinical ALI/ARDS, and chronic overexpression of a proangiogenic factor could potentially affect vascular structure and function. However, notwithstanding the possibility of changes in peripheral organs that were not assessed in this lung injury model, we observed no differences in the pulmonary expression of 84 genes involved in vascular biology prior to LPS exposure between ANGPT2^{OVR} and control^{tTA} mice. While not conclusive, this does suggest that the early induction of ANGPT2 under physiological conditions did not significantly alter pulmonary vasculature function, at least at the transcriptional level. Another limitation of this study is that the statistical significance of changes in BAL cell and protein levels assessed at different time points were not adjusted for multiple comparisons; therefore, we cannot discount the possibility of a type I (false positive) result. However, our experiments were designed principally to minimise type II (false negative) results. This is an important pragmatic consideration given limitations with sample size, since breeding double transgenic mice in large numbers represents highly labour-intensive, time-intensive and cost-intensive experiments to conduct. Therefore, we induced elevated plasma levels of ANGPT2 in transgenic mice in an effort to mimic the very high plasma levels observed in patients with ALI/ARDS and used an LPS dose that induced subsaturating effects on pulmonary inflammation and vascular leak (since we hypothesised that high ANGPT2 plasma levels would increase these parameters). In addition, our results showed high internal consistency in the biological effects demonstrated between the various time course, aptamer-mediated ANGPT2 neutralisation and lung transcriptional profiling experiments, and corroborate ANGPT2-mediated proinflammatory[44] and anti-leak activities[15] that have been independently demonstrated in other laboratories. Thus, while the changes observed in the current study were modest in magnitude, they may still represent biologically meaningful effects. Functional differences between human and mouse ANGPT2 represent another potential limitation associated with the use of the transgenic mouse model in this study. However, human and mouse ANGPT2 are 85% identical in amino acid sequence,[9] and previous *in vitro*[51] and *in vivo*[15] studies have provided evidence that hANGPT2 is capable of both blocking and inducing the phosphorylation of mouse TIE2 in a context-dependent manner.

In summary, high circulating levels of ANGPT2 exerted only modest effects on pulmonary microvascular function in mice with LPS-induced lung injury, exacerbating inflammatory cell and cytokine infiltration of the alveolar air space while attenuating specific indices of pulmonary vascular leak, with no associated benefit or detriment to survival. Supported by additional transcriptional profiling, these data suggest that elevated circulating levels of ANGPT2 may contribute to vascular homeostatic mechanisms by helping to fine-tune changes in pulmonary gene expression and function in response to proinflammatory stimuli. An important implication is that therapeutic strategies aimed at inhibiting excess circulating levels of ANGPT2 in ALI and sepsis may be less effective than approaches designed to directly activate TIE2, as previously suggested.[49 50] This study now broadens the known context-dependent activities of ANGPT2 in vivo, and offers new insight into the possible biological effects of elevated circulating ANGPT2 levels in ALI/ARDS.

REFERENCES

1 Ware LB, Matthay MA. The acute respiratory distress syndrome. *N Engl J Med* 2000;342:1334–49.
2 van der Heijden M, van Nieuw Amerongen GP, Chedamni S, *et al*. The angiopoietin-Tie2 system as a therapeutic target in sepsis and acute lung injury. *Expert Opin Ther Targets* 2009;13:39–53.
3 Gamble JR, Drew J, Trezise L, *et al*. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. *Circ Res* 2000;87:603–7.
4 Thurston G, Rudge JS, Ioffe E, *et al*. The anti-inflammatory actions of angiopoietin-1. *EXS* 2005;94:233–45.
5 Baffert F, Le T, Thurston G, *et al*. Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules. *Am J Physiol Heart Circ Physiol* 2006;290:H107–H118.
6 Thurston G, Rudge JS, Ioffe E, *et al*. Angiopoietin-1 protects the adult vasculature against plasma leakage. *Nat Med* 2000;6:460–3.
7 Thurston G, Suri C, Smith K, *et al*. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. *Science* 1999;286:2511–4.
8 Davis S, Aldrich TH, Jones PF, *et al*. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. *Cell* 1996;87:1161–9.
9 Maisonpierre PC, Suri C, Jones PF, *et al*. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. *Science* 1997;277:55–60.
10 Suri C, Jones PF, Patan S, *et al*. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. *Cell* 1996;87:1171–80.
11 Seegar TC, Eller B, Tzvetkova-Robev D, *et al*. Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands. *Mol Cell* 2010;37:643–55.
12 Teichert-Kuliszewska K, Maisonpierre PC, Jones N, *et al*. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of TIE2. *Cardiovasc Res* 2001;49:659–70.
13 Kim I, Kim JH, Moon SO, *et al*. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. *Oncogene* 2000;19:4549–52.

14 Yuan HT, Khankin EV, Karumanchi SA, *et al*. Angiopoietin 2 is a partial agonist/ antagonist of Tie2 signaling in the endothelium. *Mol Cell Biol* 2009;29:3451.

15 Daly C, Pasnikowski E, Burova E, *et al*. Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. *Proc Natl Acad Sci U S A* 2006;103:15491–6.

16 Bhandari V, Choo-Wing R, Lee CG, *et al*. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. *Nat Med* 2006;12:1286–93.

17 Gallagher DC, Parikh SM, Balonov K, *et al*. Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. *Shock* 2008;29:656–61.

18 Giuliano JS, Wheeler DS. Excess circulating angiopoietin-2 levels in sepsis: harbinger of death in the intensive care unit? *Crit Care* 2009;13:114.

19 Orfanos SE, Kotanidou A, Glynos C, *et al*. Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators. *Crit Care Med* 2007;35:199–206.

20 Parikh SM, Mammoto T, Schultz A, *et al*. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. *PLoS Med* 2006;3:e46.

21 van der Heijden M, van Nieuw Amerongen GP, Koolwijk P, *et al*. Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. *Thorax* 2008;63:903–9.

22 McIntyre LA, Fergusson DA, Cook DJ, *et al*. Fluid Resuscitation with 5% albumin versus Normal Saline in Early Septic Shock: a pilot randomized, controlled trial. *J Crit Care* 2012;27: e1–6317.

23 Lekas M, Lekas P, Mei SM, *et al*. TIE2-dependent neovascularization of the ischemic himdilimb is mediated by angiopoietin-2. *PLoS One* 2012;7:e43568.

24 White RR, Shan S, Rusconi CP, *et al*. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. *Proc Natl Acad Sci U S A* 2003;100:5028–33.

25 Rothman KJ. No adjustments are needed for multiple comparisons. *Epidemiology* 1990;1:43–6.

26 Agrawal A, Matthay MA, Kangelaris KN, *et al*. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. *Am J Respir Crit Care Med* 2013;187:736–42.

27 Calfee CS, Janz DR, Bernard GR, *et al*. Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies. *Chest* 2015;147:1539–48.

28 Ebihara I, Hirayama K, Nagai M, *et al*. Angiopoietin balance in septic shock patients with acute lung injury: effect of direct hemoperfusion with polymyxin B-immobilized fiber. *Ther Apher Dial* 2011;15:349–54.

29 Senger DR, Galli SJ, Dvorak AM, *et al*. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. *Science* 1983;219:983–5.

30 Yeo KT, Wang HH, Nagy JA, *et al*. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. *Cancer Res* 1993;53:2912–8.

31 Singh H, Milner CS, Aguilar Hernandez MM, *et al*. Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases. *Cell Signal* 2009;21:1346–50.

32 Kasten KR, Prakash PS, Unsinger J, *et al*. Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis. *Infect Immun* 2010;78:4714–22.

33 López Farré A, Riesco A, Espinosa G, *et al*. Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart. *Circulation* 1993;88:1166–71.

34 Uhl B, Zuchtriegel G, Puhr-Westerheide D, *et al*. Tissue plasminogen activator promotes postischemic neutrophil recruitment via its proteolytic and nonproteolytic properties. *Arterioscler Thromb Vasc Biol* 2014;34:1495–504.

35 Arndt PG, Young SK, Poch KR, *et al*. Systemic inhibition of the angiotensin-converting enzyme limits lipopolysaccharide-induced lung neutrophil recruitment through both bradykinin and angiotensin II-regulated pathways. *J Immunol* 2006;177:7233–41.

36 Felcht M, Luck R, Schering A, *et al*. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. *J Clin Invest* 2012;122:1991–2005.

37 Lemieux C, Maliba R, Favier J, *et al*. Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. *Blood* 2005;105:1523–30.

38 Murdoch C, Tazzyman S, Webster S, *et al*. Expression of TIE-2 by human monocytes and their responses to angiopoietin-2. *J Immunol* 2007;178:7405–11.

39 Wang X, Dai Z, Wu X, *et al*. Distinct RNA transcriptome patterns are potentially associated with angiogenesis in TIE2-expressing monocytes. *Gene* 2016;580:1–7.

40 Makinde TO, Agrawal DK. Increased expression of angiopoietins and TIE2 in the lungs of chronic asthmatic mice. *Am J Respir Cell Mol Biol* 2011;44:384–93.

41 Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. *Circ Res* 2002;90:1243–50.

42 Six I, Kureishi Y, Luo Z, *et al*. Akt signaling mediates VEGF/VPF vascular permeability in vivo. *FEBS Lett* 2002;532:67–9.

43 Yum HK, Arcaroli J, Kupfner J, *et al*. Involvement of phosphoinositide 3-kinases in neutrophil activation and the development of acute lung injury. *J Immunol* 2001;167:6601–8.

44 Fiedler U, Reiss Y, Scharpfenecker M, *et al*. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. *Nat Med* 2006;12:235–9.

45 Roviezzo F, Tsigkos S, Kotanidou A, *et al*. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. *J Pharmacol Exp Ther* 2005;314:738–44.

46 Augustin HG, Koh GY, Thurston G, *et al*. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. *Nat Rev Mol Cell Biol* 2009;10:165–77.

47 Kurniati NF, van Meurs M, Vom Hagen F, *et al*. Pleiotropic effects of angiopoietin-2 deficiency do not protect mice against endotoxin-induced acute kidney injury. *Nephrol Dial Transplant* 2013;28:567–75.

48 Hegeman MA, Hennus MP, van Meurs M, *et al*. Angiopoietin-1 treatment reduces inflammation but does not prevent ventilator-induced lung injury. *PLoS One* 2010;5:e15653.

49 David S, Ghosh CC, Kümpers P, *et al*. Effects of a synthetic PEG-ylated TIE-2 agonist peptide on endotoxemic lung injury and mortality. *Am J Physiol Lung Cell Mol Physiol* 2011;300:L851–L862.

50 Han S, Lee SJ, Kim KE, *et al*. Amelioration of sepsis by TIE2 activation-induced vascular protection. *Sci Transl Med* 2016; 8: 335- 55.

51 Reiss Y, Droste J, Heil M, *et al*. Angiopoietin-2 impairs revascularization after limb ischemia. *Circ Res* 2007;101:88–96.